Active Comparator: Efficacy Study

Important information about the Active Comparator Study

  • The results and conclusions of this single study should be interpreted in light of its limitations, including, but not limited to, the open-label design and inclusion of previously treated patients with inhaled tobramycin (TNS). A comparable study has not been conducted to verify these results
  • This study was designed and funded by Gilead Sciences, Inc. (GSI) with input from all authors on this publication. Some of the authors had consultancy with or were employees and/or shareholders of GSI

Active Comparator Trial: Co-primary efficacy endpoints6

Superiority analysis: Adjusted mean actual change (SE) in FEV1% across 3 treatment cycles

CAYSTON Superiority analysis: Adjusted mean actual change (SE) in FEV% across 3 treatment cycles

Non-inferiority analysis: Mean relative change in FEV1% at Day 28

CAYSTON Non-inferiority analysis: Mean relative change in FEV% at Day 28
Learn About the Active Comparator Trial Safety Results
NEXT